Background Antiresorptive agents are widely used to treat osteoporosis. We report the results
of a multinational randomized, double-blind study, in which postmenopausal women with …

Background Osteoporosis is a common complication of long-term glucocorticoid therapy for
which there is no well-proved preventive or restorative treatment. Methods We carried out …

Objective Risedronate, a new pyridinyl bisphosphonate, is a potent antiresorptive bone
agent. This study examines the safety and efficacy of daily, oral risedronate therapy for the …

Objective To evaluate the continued efficacy and safety of alendronate (ALN) for up to 2
years in patients receiving glucocorticoids. Methods This is a 12‐month extension of a …

Background: Reducing bisphosphonate dosing frequency may improve suboptimal adherence
to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once-…

We report here the second 2-yr extension of a clinical trial among postmenopausal women;
235 women continued blinded treatment with 5 or 10 mg alendronate daily, and 115 women …

The bisphosphonate alendronate and conjugated equine estrogens are both widely used for
the treatment of postmenopausal osteoporosis. Acting by different mechanisms, these two …

Background: Combination therapy with alendronate and estrogen for 2 years increases
bone mineral density at the spine and hip more than does therapy with either agent alone. …

OBJECTIVE: Oral alendronate sodium is a potent, specific inhibitor of osteoclast-mediated
bone resorption. To assess its efficacy and safety, a 3-year, randomized, double-blind, …

Objective: Ibandronate, a potent nitrogen-containing bisphosphonate, can be administered
with extended interval dosing. Patient preferences were assessed for once-monthly versus …